Common Contracts
4 similar Letter Agreement contracts by Drugs Made in America Acquisition Corp., Archimedes Tech SPAC Partners II Co., Mission Space Acquisition Corp.
LETTER AGREEMENT Dated [●], 2024Letter Agreement • November 7th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This letter agreement (this “Letter Agreement”) is entered into by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Sponsor”), and each other undersigned person (each such other undersigned person, an “Insider” and collectively, the “Insiders”). Reference is made to that certain underwriting agreement (the “Underwriting Agreement”) entered into or proposed to be entered into by and between the Company and Clear Street LLC, as representative of the underwriters (the “Representative”), relating to an underwritten initial public offering (the “Public Offering”), of up to 20,000,000 of the Company’s units (including up to 3,000,000 units that may be purchased to cover the underwriters’ option to purchase additional units, if any) (the “Units”), each comprised of one ordinary share of the Company, par value $0.0001 per share (“Ordinary Share”), and one right
LETTER AGREEMENT Dated [●], 2024Letter Agreement • October 30th, 2024 • Archimedes Tech SPAC Partners II Co. • Blank checks
This letter agreement (this “Letter Agreement”) is entered into by and among Archimedes Tech SPAC Partners II Co., a Cayman Islands exempted company (the “Company”), Archimedes Tech SPAC Sponsors II LLC, a Delaware limited liability company (the “Sponsor”), and each other undersigned person (each such other undersigned person, an “Insider” and collectively, the “Insiders”). Reference is made to that certain underwriting agreement (the “Underwriting Agreement”) entered into or proposed to be entered into by and between the Company and BTIG, LLC, as representative (the “Representative”) of the several underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 23,000,000 of the Company’s units (including up to 3,000,000 units that may be purchased to cover the Underwriters’ option to purchase additional units, if any) (the “Units”), each comprised of one ordinary share of the Company, par value $0.0001 per share (“Ordinary Shar
LETTER AGREEMENT Dated [●], 2024Letter Agreement • September 27th, 2024 • Drugs Made in America Acquisition Corp. • Blank checks
This letter agreement (this “Letter Agreement”) is entered into by and among Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company”), Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Sponsor”), and each other undersigned person (each such other undersigned person, an “Insider” and collectively, the “Insiders”). Reference is made to that certain underwriting agreement (the “Underwriting Agreement”) entered into or proposed to be entered into by and between the Company and Craft Capital Management LLC and EF Hutton LLC, as underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 57,500,000 of the Company’s units (including up to 7,500,000 units that may be purchased to cover the Underwriters’ option to purchase additional units, if any) (the “Units”), each comprised of one ordinary share of the Company, par value $0.0001 per share (“Ordinary Share”), and one
LETTER AGREEMENTLetter Agreement • April 11th, 2024 • Mission Space Acquisition Corp.
This letter agreement (this “Letter Agreement”) is entered into by and among Mission Space Acquisition Corp., a Cayman Islands exempted company (the “Company”), Mission Space Sponsor LLC, a Delaware limited liability company (the “Sponsor”), and each other undersigned person (each such other undersigned person, an “Insider” and collectively, the “Insiders”). Reference is made to that certain underwriting agreement (the “Underwriting Agreement”) entered into or proposed to be entered into by and between the Company, and B. Riley Securities, Inc., as representative (the “Representatives”) of the several underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”), of up to 10,000,000 of the Company’s units (including up to 1,500,000 units that may be purchased to cover the Underwriters’ option to purchase additional units, if any) (the “Units”), each comprised of one Class A ordinary share of the Company, par value $0.0001 per share (“Cla
